The Deal
Sunday, November 22, 
1:22 pm

Pac-Man drops Neurocrine, could Sepracor be near?

  Share     E-Mail    Discussion    Print Story

Pac-Man.gifPfizer, the Pac-Man of the pharmaceutical industry, has ended its partnership with San Diego biotech Neurocrine to develop and market the smaller company's insomnia treatment Indiplon. The news comes only days after CNN Money first suggested that Sepracor could be in play, and that Pfizer was one of the bidders. Sepracor's leading product is Lunesta, a sleep aid already on the market. Of course Pfizer hasn't responded to the Sepracor rumors. In the case of the Neurocrine partnership, the pharma blames delays in FDA approval of Indiplon. —Matthew Wurtzel

See story from Forbes
See story from MarketWatch
See earlier story from CNN Money
See earlier post

Continue reading below

Also on Dealscape





Post a comment





The Deal Pipeline

Deal Video


Inside The Deal: Avaya Inc.'s Mohamad Ali on the company's next target.


More video...

Crisis On Wall Street
Technology
Deals of The Decade

Community

Industry Insight

Managing your shareholder base

Growth companies and their PE sponsors should be wary of the pitfalls that arise when they layer on tiers of preferred stock.


Industry Insight

Easing the stress of distressed M&A

Corporate buyers face numerous complexities when trying to identify the right moment to purchase a distressed asset.


Editor's Note

Editor's letter: Nov. 16, 2009

Beneath the veneer of Wall Streeters beats the same heart, stirred by the same determinants of behavior.


footspacer.jpg footspacer.jpg footspacer.jpg footspacer.jpg footspacer.jpg


©Copyright 2009, The Deal, LLC. All rights reserved. Please send all technical questions, comments or concerns to the Webmaster.